MiMedx Group, Inc. Q3 2025 Earnings Release and Financial Results

MiMedx Group, Inc. announced its financial results for the third quarter of 2025, reporting record net sales of $114 million, a 35% increase year-over-year. The growth was driven by a 40% increase in Wound product sales and a 26% increase in Surgical product sales. The company achieved a GAAP net income of $17 million and an Adjusted EBITDA of $35 million, representing 31% of net sales. MiMedx also raised its 2025 net sales growth and Adjusted EBITDA expectations, anticipating mid-to-high teens percentage growth in net sales and an Adjusted EBITDA margin in the mid-20% range. The company highlighted its strategic priorities, including product portfolio innovation, expanding its Surgical footprint, and enhancing customer intimacy. MiMedx is also preparing for potential changes in Medicare reimbursement rules expected in 2026, which it believes will stabilize the industry and benefit the company in the long term.